FDA Shifts Alzheimer’s Playbook

nurse with stethoscope comforting elderly man wearing masks — Photo: Yuganov Konstantin / Shutterstock

For the first time, a simple blood draw can help confirm Alzheimer’s and guide treatment.

Story Snapshot

The Food and Drug Administration cleared the first blood test to aid Alzheimer’s diagnosis.
More blood tests followed, including one for adults as young as 40 with symptoms.
Two disease-slowing drugs now hold Food and Drug Administration approvals.
A new tau brain scan adds a sharper picture of disease activity.

What Changed: From spinal taps to a blood draw

Doctors can now use a Food and Drug Administration–cleared blood test to help confirm Alzheimer’s in symptomatic adults. The agency cleared the Lumipulse G pTau217 to beta-amyloid 1-42 plasma ratio test in May 2025 for patients 55 and older with signs of the disease. The test helps detect amyloid plaque biology without a spinal tap or costly imaging, expanding access to an answer families need. This move shifts diagnosis from rarefied clinics toward everyday care.

A second wave broadened access. The Food and Drug Administration cleared the PrecivityAD2 blood test in August 2026 for adults 40 and older who show cognitive symptoms, with defined use alongside clinical exams and memory testing. Coverage and clinic workflow studies suggest these blood tests help primary care teams sort who likely has Alzheimer’s and who should see a specialist, cutting delays that often waste a precious treatment window. Speed to clarity matters when every month counts.

The therapy toolkit is no longer empty

The Food and Drug Administration granted traditional approval to lecanemab, sold as Leqembi, after confirmatory trials showed a clinical benefit in early Alzheimer’s. The agency also approved donanemab, sold as Kisunla, for adults with Alzheimer’s disease. These antibody drugs target amyloid pathology and can modestly slow decline in carefully selected patients. That is not a cure. It is, however, more than families had even three years ago, and it fits a clear rule: diagnose earlier, treat earlier.

Imaging options advanced in lockstep. In August 2026, the Food and Drug Administration listed florquinitau F 18, marketed as Tauklarify, among that year’s novel drug approvals for brain positron emission tomography to identify tau pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease. Tau tangles track more closely with symptoms than amyloid does. Adding a tau scan to the toolbox helps doctors confirm stage, match patients to the right therapy, and monitor change with more confidence and less guesswork.

What this means for patients and families now

Primary care clinics can start workups sooner and with less friction. A blood test that suggests Alzheimer’s can prompt safety steps at home, lifestyle changes, and timely referrals. A negative result can spare some patients invasive tests and focus attention on other, treatable causes of memory loss. These changes align with common-sense medicine: faster answers, fewer roadblocks, and treatments started when they help most. They also respect patient dignity by reducing long waits and repeated, costly appointments.

Policy makers and health plans face a practical task. The Food and Drug Administration has cleared the tests and drugs; now coverage, clinic staffing, and risk management must catch up. American conservative values stress accountability and choice. That argues for clear eligibility rules, price transparency, and informed consent about benefits and risks. Families deserve straight talk: these tools can slow decline for some and guide care for many, but they do not reverse established disease. Wise stewardship will extend access without waste.

How to think about “breakthrough” without hype

The National Institutes of Health highlights rapid gains in tools to detect and track dementia, from blood biomarkers to advanced imaging and data science investments. The pattern is steady progress, not a miracle cure. Blood tests trim the path to diagnosis. Antibody drugs nudge the slope of decline. Tau scans sharpen decision-making. Put together, these steps make daily care better. The real breakthrough is a working system: test, confirm, treat, and monitor, all earlier and closer to home.